logo-loader
viewCB2 Insights Inc.

CB2 Insights strengthens presence in UK medical cannabis market with MyAccess Clinics tie-up

MyAccess Clinics operates multiple clinics in the UK and is focused on providing care for patients with unmet needs

CB2 Insights -
The firm's Electronic Data Capture (EDC) software will be used to manage patient data

CB2 Insights (CSE:CBII) (OTCMKTS:CBIIF), the medical cannabis data group, revealed it had increased its market presence in the UK, saying it will license its technology to MyAccess Clinics (MAC) to manage their patient data.

The latter operates multiple clinics in the UK and is focused on providing care for patients with unmet needs, which licensed medicines have failed to address.

READ: CB2 Insights enters Colombian medical cannabis market

It has chosen CB2 Insights’ Electronic Data Capture (EDC) software to manage the complex and layered world of patient data in its growing clinic base.

"The UK market continues to blossom at a rapid pace, and we are proud that our research and data technology assets continue to be sought to expedite growth in the market,” said Prad Sekar, the CEO at CB2 Insights

"MyAccess Clinics has an exceptional and comprehensive vision for its development in the UK’s medical cannabis market and we are excited to be a part of that effort."

The EDC software has been used throughout the US and Canada and is purpose-built for medical cannabis operations.

"As a company, we are proud to be one of the first to service the emerging UK medical cannabis market," said Graham Woodward, MyAccess Clinics' clinical director.

Integral part

"CB2 Insights’ software will play an integral part in the administration of our clinics and will increase our ability to manage data, thereby improving our patient care.”

It comes after in July this year, CB2 Insights was selected as the exclusive research technology platform for UK-based Drug Science and its medical cannabis pilot program, involving 20,000 patients.

MyAccess Clinics is a wholly-owned subsidiary of the leading global medical cannabis company Althea Group Holdings Ltd (ASX:AGH).

Shares surged 7.7% to C$0.14 in Toronto.

Contact the author at [email protected]

Quick facts: CB2 Insights Inc.

Price: 0.125 CAD

CSE:CBII
Market: CSE
Market Cap: $10 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 12/17/2019

2 min read